{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:26:03Z","timestamp":1787970363465,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13300-025-01712-z","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:42:29Z","timestamp":1743370949000},"page":"1077-1105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Therapeutic Potential of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Peripheral Neuropathy"],"prefix":"10.1007","volume":"16","author":[{"given":"Theodoros","family":"Panou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"10","key":"1712_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","volume":"19","author":"CW Hicks","year":"2019","unstructured":"Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19(10):86.","journal-title":"Curr Diab Rep"},{"key":"1712_CR2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S252\u201365.","DOI":"10.2337\/dc25-S012"},{"key":"1712_CR3","doi-asserted-by":"publisher","unstructured":"Savelieff MG, Elafros MA, Viswanathan V, Jensen TS, Bennett DL, Feldman EL. The global and regional burden of diabetic peripheral neuropathy. Nat Rev Neurol. 2024;1:17\u201331. https:\/\/doi.org\/10.1038\/s41582-024-01041-y.","DOI":"10.1038\/s41582-024-01041-y"},{"issue":"10","key":"1712_CR4","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","volume":"66","author":"J Goldney","year":"2023","unstructured":"Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia. 2023;66(10):1832\u201345.","journal-title":"Diabetologia"},{"key":"1712_CR5","doi-asserted-by":"crossref","unstructured":"Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;5(5):CD012204.","DOI":"10.1002\/14651858.CD012204.pub2"},{"issue":"4","key":"1712_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11154-023-09807-3","volume":"24","author":"N Garc\u00eda-Casares","year":"2023","unstructured":"Garc\u00eda-Casares N, Gonz\u00e1lez-Gonz\u00e1lez G, de la Cruz-Cosme C, et al. Effects of GLP-1 receptor agonists on neurological complications of diabetes. Rev Endocr Metab Disord. 2023;24(4):655\u201372.","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"1712_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","volume":"4","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525\u201336.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1712_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000940","volume":"8","author":"SH Baik","year":"2020","unstructured":"Baik SH, McDonald CJ. Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2020;8(1): e000940.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"1712_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s13300-023-01506-1","volume":"15","author":"E Gouveri","year":"2024","unstructured":"Gouveri E, Popovic DS, Papanas N. Potential new therapeutic implications of semaglutide: new colours of the rainbow? Diabetes Ther. 2024;15(1):13\u20138.","journal-title":"Diabetes Ther"},{"issue":"9","key":"1712_CR10","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s11064-008-9646-4","volume":"33","author":"SC Biswas","year":"2008","unstructured":"Biswas SC, Buteau J, Greene LA. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res. 2008;33(9):1845\u201351.","journal-title":"Neurochem Res"},{"key":"1712_CR11","doi-asserted-by":"crossref","unstructured":"Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568. Drugs R D. 2004;5(1):35\u201340.","DOI":"10.2165\/00126839-200405010-00007"},{"issue":"5","key":"1712_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/bcpt.13169","volume":"124","author":"MKK Yap","year":"2019","unstructured":"Yap MKK, Misuan N. Exendin-4 from Heloderma suspectum venom: from discovery to its latest application as type II diabetes combatant. Basic Clin Pharmacol Toxicol. 2019;124(5):513\u201327.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"1712_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/NEN.0b013e3182580673","volume":"71","author":"M Kan","year":"2012","unstructured":"Kan M, Guo G, Singh B, Singh V, Zochodne DW. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. J Neuropathol Exp Neurol. 2012;71(6):494\u2013510.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"9","key":"1712_CR14","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2337\/db10-1462","volume":"60","author":"T Himeno","year":"2011","unstructured":"Himeno T, Kamiya H, Naruse K, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes. 2011;60(9):2397\u2013406.","journal-title":"Diabetes"},{"issue":"5","key":"1712_CR15","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/j.1476-5381.2011.01272.x","volume":"164","author":"WJ Liu","year":"2011","unstructured":"Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol. 2011;164(5):1410\u201320.","journal-title":"Br J Pharmacol"},{"issue":"21","key":"1712_CR16","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1007\/s00018-010-0398-3","volume":"67","author":"P Luciani","year":"2010","unstructured":"Luciani P, Deledda C, Benvenuti S, et al. Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model. Cell Mol Life Sci. 2010;67(21):3711\u201323.","journal-title":"Cell Mol Life Sci"},{"key":"1712_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175896","volume":"954","author":"S Pandey","year":"2023","unstructured":"Pandey S, Mangmool S, Madreiter-Sokolowski CT, Wichaiyo S, Luangmonkong T, Parichatikanond W. Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor\/Epac\/Akt signalling. Eur J Pharmacol. 2023;954: 175896.","journal-title":"Eur J Pharmacol"},{"key":"1712_CR18","doi-asserted-by":"publisher","first-page":"9426014","DOI":"10.1155\/2019\/9426014","volume":"2019","author":"MS Mohiuddin","year":"2019","unstructured":"Mohiuddin MS, Himeno T, Inoue R, et al. Glucagon-like peptide-1 receptor agonist protects dorsal root ganglion neurons against oxidative insult. J Diabetes Res. 2019;2019:9426014.","journal-title":"J Diabetes Res"},{"issue":"3","key":"1712_CR19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1124\/jpet.300.3.958","volume":"300","author":"T Perry","year":"2002","unstructured":"Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300(3):958\u201366.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1712_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00418-015-1333-3","volume":"144","author":"M Tsukamoto","year":"2015","unstructured":"Tsukamoto M, Niimi N, Sango K, Takaku S, Kanazawa Y, Utsunomiya K. Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA. Histochem Cell Biol. 2015;144(3):249\u201359.","journal-title":"Histochem Cell Biol"},{"key":"1712_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.12659\/MSMBR.891168","volume":"20","author":"I Komsuoglu Celikyurt","year":"2014","unstructured":"Komsuoglu Celikyurt I, Mutlu O, Ulak G, et al. Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes. Med Sci Monit Basic Res. 2014;20:112\u20137.","journal-title":"Med Sci Monit Basic Res"},{"issue":"11","key":"1712_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1463-1326.2011.01431.x","volume":"13","author":"CG Jolivalt","year":"2011","unstructured":"Jolivalt CG, Fineman M, Deacon CF, Carr RD, Calcutt NA. GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab. 2011;13(11):990\u20131000.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1712_CR23","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1111\/dom.14507","volume":"23","author":"LS Gasbjerg","year":"2021","unstructured":"Gasbjerg LS, Bari EJ, Christensen M, Knop FK. Exendin(9\u201339)NH2: Recommendations for clinical use based on a systematic literature review. Diabetes Obes Metab. 2021;23(11):2419\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1712_CR24","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/biom12101338","volume":"12","author":"E Kornelius","year":"2022","unstructured":"Kornelius E, Tsou SH, Chang CC, et al. Liraglutide attenuates glucolipotoxicity-induced rsc96 schwann cells\u2019 inflammation and dysfunction. Biomolecules. 2022;12(10):1338.","journal-title":"Biomolecules"},{"issue":"1338","key":"1712_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1098\/rstb.1996.0042","volume":"351","author":"DR Tomlinson","year":"1996","unstructured":"Tomlinson DR, Fernyhough P, Diemel LT. Neurotrophins and peripheral neuropathy. Phil Trans R Soc Lond B. 1996;351(1338):455\u201362.","journal-title":"Phil Trans R Soc Lond B"},{"issue":"5","key":"1712_CR26","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s11845-024-03716-3","volume":"193","author":"A Gaur","year":"2024","unstructured":"Gaur A, Varatharajan S, Balan Y, et al. Brain-derived neurotrophic factor (BDNF) and other neurotrophic factors in type 2 diabetes mellitus and their association with neuropathy. Ir J Med Sci. 2024;193(5):2287\u201392.","journal-title":"Ir J Med Sci"},{"issue":"2","key":"1712_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/fcp.12329","volume":"32","author":"E Gumuslu","year":"2018","unstructured":"Gumuslu E, Cine N, Ertan M, Mutlu O, Komsuoglu Celikyurt I, Ulak G. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin\/nicotinamide-induced diabetic mice. Fundam Clin Pharmacol. 2018;32(2):174\u201380.","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"1712_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","volume":"22","author":"RA Fontanella","year":"2024","unstructured":"Fontanella RA, Ghosh P, Pesapane A, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024;22(1):114.","journal-title":"J Transl Med"},{"issue":"10295","key":"1712_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0140-6736(21)01390-8","volume":"398","author":"TM Tan","year":"2021","unstructured":"Tan TM, Khoo B. Tirzepatide and the new era of twincretins for diabetes. Lancet. 2021;398(10295):95\u20137.","journal-title":"Lancet"},{"issue":"5","key":"1712_CR30","doi-asserted-by":"publisher","first-page":"E188","DOI":"10.25011\/cim.v40i5.28624","volume":"40","author":"A Senyigit","year":"2017","unstructured":"Senyigit A, Tabak O, Orhanoglu T, et al. Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes. Clin Invest Med. 2017;40(5):E188\u201399.","journal-title":"Clin Invest Med"},{"issue":"10","key":"1712_CR31","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.bbadis.2019.07.008","volume":"1865","author":"T H\u00f6rbelt","year":"2019","unstructured":"H\u00f6rbelt T, Knebel B, Fahlbusch P, et al. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver. Biochim Biophys Acta Mol Basis Dis. 2019;1865(10):2671\u201384.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"1712_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","volume":"67","author":"R Dhanapalaratnam","year":"2024","unstructured":"Dhanapalaratnam R, Issar T, Lee ATK, et al. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia. 2024;67(3):561\u20136.","journal-title":"Diabetologia"},{"issue":"12","key":"1712_CR33","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1111\/ene.15534","volume":"29","author":"R Dhanapalaratnam","year":"2022","unstructured":"Dhanapalaratnam R, Issar T, Poynten AM, Milner KL, Kwai NCG, Krishnan AV. Diagnostic accuracy of nerve ultrasonography for the detection of peripheral neuropathy in type 2 diabetes. Eur J Neurol. 2022;29(12):3571\u20139.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1712_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1152\/jn.00228.2024","volume":"133","author":"R Dhanapalaratnam","year":"2025","unstructured":"Dhanapalaratnam R, Issar T, Poynten AM, Milner KL, Kwai NC, Krishnan AV. Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy. J Neurophysiol. 2025;133(1):14\u201321.","journal-title":"J Neurophysiol"},{"issue":"8","key":"1712_CR35","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jdiacomp.2015.07.013","volume":"29","author":"M Jaiswal","year":"2015","unstructured":"Jaiswal M, Martin CL, Brown MB, et al. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complications. 2015;29(8):1287\u201394.","journal-title":"J Diabetes Complications"},{"issue":"10","key":"1712_CR36","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.clinph.2021.05.033","volume":"132","author":"T Issar","year":"2021","unstructured":"Issar T, Kwai NCG, Poynten AM, Arnold R, Milner KL, Krishnan AV. Effect of exenatide on peripheral nerve excitability in type 2 diabetes. Clin Neurophysiol. 2021;132(10):2532\u20139.","journal-title":"Clin Neurophysiol"},{"key":"1712_CR37","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.3390\/ijms25168881","volume":"25","author":"M Yamaguchi","year":"2024","unstructured":"Yamaguchi M, Noda-Asano S, Inoue R, et al. Dipeptidyl peptidase (DPP)-4 inhibitors and pituitary adenylate cyclase-activating polypeptide, a DPP-4 substrate, extend neurite outgrowth of mouse dorsal root ganglia neurons: a promising approach in diabetic polyneuropathy treatment. Int J Mol Sci. 2024;25:8881.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1712_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/0167-4838(91)90284-7","volume":"1076","author":"J Rahfeld","year":"1991","unstructured":"Rahfeld J, Schierhorn M, Hartrodt B, Neubert K, Heins J. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim Biophys Acta. 1991;1076(2):314\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1712_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.metabol.2009.12.031","volume":"60","author":"RF Alponti","year":"2011","unstructured":"Alponti RF, Frezzatti R, Barone JM, Alegre Vde S, Silveira PF. Dipeptidyl peptidase IV in the hypothalamus and hippocampus of monosodium glutamate obese and food-deprived rats. Metabolism. 2011;60(2):234\u201342.","journal-title":"Metabolism"},{"issue":"8","key":"1712_CR40","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00125-015-3608-6","volume":"58","author":"JJ Meier","year":"2015","unstructured":"Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now? Diabetologia. 2015;58(8):1745\u201350.","journal-title":"Diabetologia"},{"key":"1712_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.arcmed.2009.09.005","volume":"40","author":"HY Jin","year":"2009","unstructured":"Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res. 2009;40:536\u201344.","journal-title":"Arch Med Res"},{"key":"1712_CR42","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/jnc.13439","volume":"136","author":"K Tsuboi","year":"2016","unstructured":"Tsuboi K, Mizukami H, Inaba W, Baba M, Yagihashi S. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: effects on peripheral sensory nerve function, structure and molecular changes. J Neurochem. 2016;136:859\u201370.","journal-title":"J Neurochem"},{"issue":"8008","key":"1712_CR43","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41586-024-07237-y","volume":"628","author":"YZ Lu","year":"2024","unstructured":"Lu YZ, Nayer B, Singh SK, et al. CGRP sensory neurons promote tissue healing via neutrophils and macrophages. Nature. 2024;628(8008):604\u201311.","journal-title":"Nature"},{"issue":"5","key":"1712_CR44","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/glia.23755","volume":"68","author":"AR Hackett","year":"2020","unstructured":"Hackett AR, Strickland A, Milbrandt J. Disrupting insulin signalling in Schwann cells impairs myelination and induces a sensory neuropathy. Glia. 2020;68(5):963\u201378.","journal-title":"Glia"},{"key":"1712_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/jpet.111.181529","volume":"340","author":"R Bianchi","year":"2012","unstructured":"Bianchi R, Cervellini I, Porretta-Serapiglia C, et al. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. J Pharmacol Exp Ther. 2012;340:64\u201372.","journal-title":"J Pharmacol Exp Ther"},{"key":"1712_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154232","volume":"107","author":"D Guo","year":"2020","unstructured":"Guo D, Mizukami H, Osonoi S, et al. Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and \u03b2-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats. Metabolism. 2020;107: 154232.","journal-title":"Metabolism"},{"issue":"2","key":"1712_CR47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733\u201394.","journal-title":"Physiol Rev"},{"issue":"1","key":"1712_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1046\/j.1471-4159.1997.69010084.x","volume":"69","author":"R Poppe","year":"1997","unstructured":"Poppe R, Karbach U, Gambaryan S, et al. Expression of the Na+-D-glucose cotransporter SGLT1 in neurons. J Neurochem. 1997;69(1):84\u201394.","journal-title":"J Neurochem"},{"key":"1712_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7555\/JBR.26.20110054","volume":"26","author":"AK Sharma","year":"2012","unstructured":"Sharma AK, Sharma A, Kumari R, et al. Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats. J Biomed Res. 2012;26:200\u201310.","journal-title":"J Biomed Res"},{"issue":"4","key":"1712_CR50","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s10072-020-04681-2","volume":"42","author":"A Syngle","year":"2021","unstructured":"Syngle A, Chahal S, Vohra K. Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study. Neurol Sci. 2021;42(4):1429\u201336.","journal-title":"Neurol Sci"},{"issue":"4","key":"1712_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1590\/0004-2730000002914","volume":"58","author":"JI Barros","year":"2014","unstructured":"Barros JI, Fechine FV, Montenegro J\u00fanior RM, et al. Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2014;58(4):369\u201376.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"8","key":"1712_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308734","volume":"19","author":"E Nakatani","year":"2024","unstructured":"Nakatani E, Ohno H, Satoh T, et al. Comparing the effects of biguanides and dipeptidyl peptidase-4 inhibitors on cardio-cerebrovascular outcomes, nephropathy, retinopathy, neuropathy, and treatment costs in diabetic patients. PLoS ONE. 2024;19(8): e0308734.","journal-title":"PLoS ONE"},{"key":"1712_CR53","doi-asserted-by":"crossref","unstructured":"Kolaczynski WM, Hankins M, Ong SH, Richter H, Clemens A, Toussi M. Microvascular outcomes in patients with type 2 diabetes treated with vildagliptin vs. sulfonylurea: a retrospective study using German electronic medical records. Diabetes Ther. 2016;7(3):483\u2013496.","DOI":"10.1007\/s13300-016-0177-8"},{"key":"1712_CR54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/B978-0-12-381517-0.00012-6","volume":"84","author":"PM Hellstr\u00f6m","year":"2010","unstructured":"Hellstr\u00f6m PM. Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility. Vitam Horm. 2010;84:319\u201329.","journal-title":"Vitam Horm"},{"issue":"8","key":"1712_CR55","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/dom.14734","volume":"24","author":"DSH Bell","year":"2022","unstructured":"Bell DSH. Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. Diabetes Obes Metab. 2022;24(8):1423\u20138.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01712-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01712-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01712-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:03:16Z","timestamp":1747472596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01712-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01712-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Theodoros Panou has nothing to disclose. Evanthia Gouveri has attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly and Boehringer Ingelheim; and received speaker honoraria from Boehringer-Ingelheim, Sanofi and Menarini. Djordje S Popovic declares associations with Abbott, Alkaloid, Amicus, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris and W\u00f6rwag Pharma. Dimitrios Papazoglou declares associations with Menarini, Novo Nordisk, Astra-Zeneca, Boehringer Ingelheim and Sanofi-Aventis. Nikolaos Papanas has been an advisory board member of Astra-Zeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for Astra-Zeneca, Bayer, Boehringer Ingelheim, Eli-Lilly, Elpen, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Eli-Lilly, Galenica, Menarini, Novo Nordisk, Pfizer and Sanofi-Aventis. Nikolaos Papanas is an Editorial Board member of Diabetes Therapy. Nikolaos Papanas was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}